International Biotechnology Trust PLC is an investment fund managing more than $297 billion ran by James Costine. There are currently 65 companies in Mr. Costine’s portfolio. The largest investments include AMGEN and Incyte, together worth $42 billion.
As of 7th November 2023, International Biotechnology Trust PLC’s top holding is 79,246 shares of AMGEN currently worth over $21.3 billion and making up 7.2% of the portfolio value.
Relative to the number of outstanding shares of AMGEN, International Biotechnology Trust PLC owns more than approximately 0.1% of the company.
In addition, the fund holds 358,454 shares of Incyte worth $20.7 billion, whose value fell approximately 0.1% in the past six months.
The third-largest holding is Gilead Sciences Inc Commo worth $17.5 billion and the next is Intra-Cellular Therapies Inc worth $16.5 billion, with 317,856 shares owned.
Currently, International Biotechnology Trust PLC's portfolio is worth at least $297 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The International Biotechnology Trust PLC office and employees reside in London, United Kingdom. According to the last 13-F report filed with the SEC, James Costine serves as the Authorised Signatory at International Biotechnology Trust PLC.
In the most recent 13F filing, International Biotechnology Trust PLC revealed that it had opened a new position in
Astrazeneca Plc Sponsored and bought 46,500 shares worth $3.15 billion.
The investment fund also strengthened its position in Gilead Sciences Inc Commo by buying
89,000 additional shares.
This makes their stake in Gilead Sciences Inc Commo total 233,584 shares worth $17.5 billion.
On the other hand, there are companies that International Biotechnology Trust PLC is getting rid of from its portfolio.
International Biotechnology Trust PLC closed its position in Apellis Pharms. on 14th November 2023.
It sold the previously owned 129,700 shares for $11.8 billion.
James Costine also disclosed a decreased stake in AMGEN by 0.3%.
This leaves the value of the investment at $21.3 billion and 79,246 shares.
The two most similar investment funds to International Biotechnology Trust PLC are Stokes Capital Advisors and Coppell Advisory Solutions. They manage $297 billion and $297 billion respectively.
International Biotechnology Trust PLC’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 50.3% of
the total portfolio value.
The fund focuses on investments in the United States as
49.2% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
9% of the total holdings value.
On the other hand, small-cap stocks make up only 1.5% of the portfolio.
The average market cap of the portfolio companies is close to $11.2 billion.
These positions were updated on November 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| AMGEN Inc. |
32.41%
79,246
|
$21,297,363,000 | 7.17% |
| Incyte Corp. |
No change
358,454
|
$20,704,303,000 | 6.97% |
| Gilead Sciences Inc Commo |
61.56%
233,584
|
$17,507,121,000 | 5.90% |
| Intra-Cellular Therapies Inc |
79.73%
317,856
|
$16,547,583,000 | 5.57% |
| Biomarin Pharmaceutical I |
161.96%
153,656
|
$13,595,483,000 | 4.58% |
| Apellis Pharms. |
Closed
129,700
|
$11,810,482,000 | |
| Supernus Pharmaceuticals Inc |
18.53%
426,500
|
$11,754,340,000 | 3.96% |
| Vera Therapeutics |
22.24%
758,355
|
$10,381,880,000 | 3.50% |
| Biogen Inc Common Stock |
265.45%
40,200
|
$10,333,812,000 | 3.48% |
| Harmony Biosciences Holdi |
44.87%
314,500
|
$10,306,165,000 | 3.47% |
| Mirati Therapeutics Inc C |
16.92%
216,000
|
$9,404,640,000 | 3.17% |
| Ultragenyx Pharmaceutical Inc. |
212.36%
250,052
|
$8,914,354,000 | 3.00% |
| Uniqure N.v. Com Eur0.05 |
7,909.68%
1,241,500
|
$8,330,465,000 | 2.81% |
| Aurinia Pharmaceuticals I |
81.43%
1,040,530
|
$8,074,513,000 | 2.72% |
| United Therapeutics Corp |
35.63%
33,959
|
$7,657,755,000 | 2.58% |
| Vertex Pharmaceuticals In |
No change
21,000
|
$7,302,540,000 | 2.46% |
| Regeneron Pharmaceuticals, Inc. |
67.23%
8,847
|
$7,278,338,000 | 2.45% |
| Illumina Inc |
No change
50,500
|
$6,932,640,000 | 2.34% |
| Horizon Therapeutics |
Closed
67,000
|
$6,890,950,000 | |
| Travere Therapeutics Inc |
Closed
441,019
|
$6,769,642,000 | |
| Alnylam Pharmaceuticals I |
54.90%
36,800
|
$6,517,280,000 | 2.20% |
| Amylyx Pharms. |
1,080.00%
295,000
|
$5,398,500,000 | 1.82% |
| Krystal Biotech Inc |
0.32%
46,092
|
$5,344,828,000 | 1.80% |
| Karuna Therapeutics Inc C |
18.68%
30,500
|
$5,157,245,000 | 1.74% |
| Axsome Therapeutics Inc |
No change
58,300
|
$4,071,089,000 | 1.37% |
| Erasca Inc Com |
35.06%
1,926,000
|
$3,794,220,000 | 1.28% |
| Acadia Pharmaceuticals In |
19.01%
179,702
|
$3,739,599,000 | 1.26% |
| Revance Therapeutics Inc |
No change
288,726
|
$3,308,800,000 | 1.11% |
| Neurocrine Biosciences In |
58.07%
28,877
|
$3,247,219,000 | 1.09% |
| Sarepta Therapeutics Inc |
42.02%
26,700
|
$3,234,972,000 | 1.09% |
| Rocket Pharmaceuticals In |
No change
156,000
|
$3,193,320,000 | 1.08% |
| Denali Therapeutics Inc C |
18.09%
154,000
|
$3,172,400,000 | 1.07% |
| Astrazeneca Plc Sponsored |
Opened
46,500
|
$3,148,515,000 | 1.06% |
| Xenon Pharmaceuticals Inc |
258.82%
91,500
|
$3,121,980,000 | 1.05% |
| CRISPR Therapeutics AG |
Opened
63,000
|
$2,858,940,000 | 0.96% |
| Madrigal Pharmaceuticals Inc |
No change
18,300
|
$2,669,421,000 | 0.90% |
| Legend Biotech Corp |
No change
38,000
|
$2,551,320,000 | 0.86% |
| Halozyme Therapeutics Inc. |
34.87%
62,200
|
$2,376,040,000 | 0.80% |
| Marinus Pharmaceuticals I |
222.22%
290,000
|
$2,337,400,000 | 0.79% |
| Beigene Ltd Sponsored Adr |
45.98%
12,700
|
$2,281,555,000 | 0.77% |
| Jazz Pharmaceuticals plc |
No change
17,200
|
$2,225,164,000 | 0.75% |
| Mirum Pharmaceuticals Inc |
No change
67,500
|
$2,128,950,000 | 0.72% |
| Iovance Biotherapeutics I |
584.62%
445,000
|
$2,024,750,000 | 0.68% |
| Ionis Pharmaceuticals Inc |
No change
43,000
|
$1,949,190,000 | 0.66% |
| Zai Lab Ltd Adr |
No change
78,958
|
$1,917,890,000 | 0.65% |
| Genmab -sp Adr |
Opened
44,300
|
$1,561,575,000 | 0.53% |
| Celldex Therapeutics Inc. |
No change
48,099
|
$1,322,242,000 | 0.45% |
| Cogent Biosciences, Inc. |
Opened
135,000
|
$1,313,550,000 | 0.44% |
| Dyne Therapeutics, Inc. |
54.20%
137,751
|
$1,231,494,000 | 0.41% |
| NovoCure Ltd |
131.25%
74,000
|
$1,193,620,000 | 0.40% |
| Amicus Therapeutics Inc C |
Opened
90,000
|
$1,092,600,000 | 0.37% |
| Cytokinetics Inc Common S |
No change
37,000
|
$1,090,020,000 | 0.37% |
| Guardant Health Inc |
No change
36,500
|
$1,081,130,000 | 0.36% |
| Insmed Inc Com Par $.01 |
No change
40,100
|
$1,012,124,000 | 0.34% |
| Blueprint Medicines Corp |
Opened
20,000
|
$1,002,200,000 | 0.34% |
| Sage Therapeutics Inc |
Closed
20,000
|
$939,400,000 | |
| Akero Therapeutics Inc |
76.44%
18,489
|
$935,174,000 | 0.32% |
| Kezar Life Sciences Inc |
Opened
703,825
|
$830,514,000 | 0.28% |
| Hutchmed China Ltd |
Closed
68,000
|
$816,000,000 | |
| Intellia Therapeutics Inc |
No change
24,000
|
$757,920,000 | 0.26% |
| Prothena Corp Plc Usd0.01 |
Opened
15,000
|
$722,850,000 | 0.24% |
| Agios Pharmaceuticals Inc |
No change
24,000
|
$593,520,000 | 0.20% |
| Beam Therapeutics Inc. |
No change
23,500
|
$564,705,000 | 0.19% |
| Ventyx Biosciences Inc Co |
No change
15,000
|
$520,650,000 | 0.18% |
| Vir Biotechnology Inc |
Opened
47,000
|
$439,920,000 | 0.15% |
| I-mab Sponsored Ads |
No change
310,499
|
$409,859,000 | 0.14% |
| PTC Therapeutics Inc |
No change
17,000
|
$380,630,000 | 0.13% |
| Arvinas Inc |
No change
17,000
|
$333,540,000 | 0.11% |
| Protagonist Therapeutics Inc |
No change
19,900
|
$331,932,000 | 0.11% |
| Relmada Therapeutics Inc |
No change
10,000
|
$30,000,000 | 0.01% |
| No transactions found | |||
| Showing first 500 out of 70 holdings | |||